Target intelligence / Profile preview

Long intergenic non-protein coding RNA 960 (LINC00960)

Target
LINC00960
Molecular classification
Long non-coding RNA (lncRNA), Intergenic lncRNA
01

Overview

Long intergenic non-protein coding RNA 960 (LINC00960) is a human long non-coding RNA gene located on chromosome 3, classified as an intergenic lncRNA. It is upregulated in several cancers, including pancreatic ductal adenocarcinoma, lung adenocarcinoma, triple-negative breast cancer, and bladder cancer. LINC00960 acts as a molecular sponge for multiple microRNAs—such as miR-146a-5p, miR-124a, miR-34a-5p, miR-16-5p, and miR-183-5p—thereby enhancing the expression of oncogenic proteins including IRAK1, SphK1, BMI1, KRAS, and AKT3. Functional studies demonstrate that LINC00960 promotes cancer cell proliferation, migration, invasion, and correlates with a poor prognosis and more aggressive tumor phenotype. Its potential as a prognostic biomarker and therapeutic target is under investigation, though it is not yet directly targeted by approved drugs.

Other names
LINC00960 (HGNC symbol)long intergenic non-protein coding RNA 960
02

Mechanism of action

Drugs targeting LINC00960 would likely aim to inhibit its function or expression, potentially using antisense oligonucleotides, siRNA, or small molecules to disrupt its sponge activity for specific microRNAs. Detailed mechanisms are not clinically established, as no approved drugs are reported.

03

Biological functions

Molecular sponge for microRNAs (miR-146a-5p, miR-124a, miR-34a-5p, miR-16-5p, miR-183-5p)Regulation of cell proliferationRegulation of cell migration and invasionRegulation of cell differentiationRegulation of cytoskeleton organization and microtubule dynamicsSuppression of cell death and autophagy
04

Disease associations

Cancer: implicated in pancreatic ductal adenocarcinoma, lung adenocarcinoma, triple-negative breast cancer, bladder cancerPoor clinical outcomes and aggressive phenotype correlation
05

Safety considerations

Therapeutic targeting of lncRNAs may present off-target effects due to broad roles in cellular regulation. Specific safety concerns for LINC00960-targeted therapies are not detailed in the current literature.
06

Biomarkers

High LINC00960 expression serves as a prognostic biomarker for poor outcome/aggressiveness in several cancers, including triple-negative breast cancer and lung adenocarcinoma

Beyond the preview

Go deeper on Long intergenic non-protein coding RNA 960 (LINC00960).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Long intergenic non-protein coding RNA 960 (LINC00960).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call